Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) by 17.02 percent. The company reported quarterly sales of $16.000 million which missed the analyst consensus estimate of $17.681 million by 9.51 percent. This is a 3.07 percent decrease over sales of $16.506 million the same period last year.